92 related articles for article (PubMed ID: 1829914)
1. Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases.
de Forni M; Lachau S; Huguet F; Canal P; Laurent G; Chevreau C; Roche H; Bugat R
Eur J Cancer; 1991; 27(6):735-9. PubMed ID: 1829914
[TBL] [Abstract][Full Text] [Related]
2. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone.
Greidanus J; de Vries EG; Mulder NH; Sleijfer DT; Uges DR; Oosterhuis B; Willemse PH
J Clin Oncol; 1989 Jun; 7(6):790-7. PubMed ID: 2715807
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of 14-day continuous intravenous infusion mitoxantrone.
Kreisle WH; Alberts DS; List AF; McCloskey T; Plezia P; Peng YM; George M
Anticancer Drugs; 1991 Jun; 2(3):251-9. PubMed ID: 1802019
[TBL] [Abstract][Full Text] [Related]
4. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
Smit EF; Willemse PH; Sleijfer DT; Uges DR; Postmus PE; Meijer S; Terheggen PM; Mulder NH; de Vries EG
J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
[TBL] [Abstract][Full Text] [Related]
5. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
Wilson WH; Berg SL; Bryant G; Wittes RE; Bates S; Fojo A; Steinberg SM; Goldspiel BR; Herdt J; O'Shaughnessy J
J Clin Oncol; 1994 Aug; 12(8):1621-9. PubMed ID: 7913721
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.
Pusztai L; Holmes FA; Fraschini G; Hortobagyi GN
Cancer Chemother Pharmacol; 1999; 43(1):86-91. PubMed ID: 9923546
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients.
Bugat R; Robert J; Herrera A; Pinel MC; Huet S; Chevreau C; Boussin G; Roquain J; Carton M
Eur J Cancer Clin Oncol; 1989 Mar; 25(3):505-11. PubMed ID: 2703005
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy.
Yang J; Shi Y; Li C; Gui L; Zhao X; Liu P; Han X; Song Y; Li N; Du P; Zhang S
Cancer Chemother Pharmacol; 2014 Sep; 74(3):637-46. PubMed ID: 25034977
[TBL] [Abstract][Full Text] [Related]
11. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.
Mulder PO; Sleijfer DT; Willemse PH; de Vries EG; Uges DR; Mulder NH
Cancer Res; 1989 Aug; 49(16):4654-8. PubMed ID: 2545349
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
13. 14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate.
Kantoff PW; Block C; Letvak L; George M
Am J Clin Oncol; 1993 Dec; 16(6):489-91. PubMed ID: 8256762
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
[TBL] [Abstract][Full Text] [Related]
16. High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial.
Pérez-Gracia JL; Colomer R; Ruiz-Casado A; Arcediano A; Tornamira MV; Gómez-Martin C; Valentin V; Mendiola C; Cortés-Funes H; Hornedo J
Bone Marrow Transplant; 2001 Jan; 27(2):117-23. PubMed ID: 11281378
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration.
Alberts DS; Surwit EA; Peng YM; McCloskey T; Rivest R; Graham V; McDonald L; Roe D
Cancer Res; 1988 Oct; 48(20):5874-7. PubMed ID: 3167842
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
